These results have been provided by the study of DiNardo et al. in a cohort of 179 patients with R/R AML harboring IDH1 mutation treated with 500 mg oral ivosidenib resulting in an overall response rate (ORR) of 41%, 21% complete response (CR), and 30% hematological improvement [49]. This evidence concerns the gene IDH1 and acute myeloid leukemia.